Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1957-1964

  Okada, Masashi ^a   Shibuya, Keita ^a,b,c   Sato, Atsushi ^a   Seino, Shizuka ^a,b,c   Watanabe, Eriko ^a,b,c   Suzuki, Shuhei ^a   Seino, Manabu ^a   Kitanaka, Chifumi ^a,b,c  

^a YAMAGATA UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Cancer stem cell; JNK; Lung cancer; Tumorigenicity; Xenograft analysis

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTHRACENES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84882659387     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2655     Document Type: Article

References (34)

1. Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Cell Biol 19: 142-149, 2007.
2. Kennedy NJ and Davis RJ: Role of JNK in tumor development. Cell Cycle 2: 199-201, 2003.
3. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549, 2009.
4. Chen F: JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res 72: 379-386, 2012.
5. Kitanaka C, Sato A and Okada M: JNK signaling in the control of the tumor-initiating capacity associated with cancer stem cells. Genes Cancer: January 22, 2013 (Epub ahead of print). doi: 10.1177/1947601912474892.
6. Matsuda K, Sato A, Okada M, et al: Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci Rep 2: 516, 2012.
7. Yoon CH, Kim MJ, Kim RK, et al: c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene 31: 4655-4666, 2012.
8. Yu Y, Ramena G and Elble RC: The role of cancer stem cells in relapse of solid tumors. Front Biosci 4: 1528-1541, 2012.
9. Malik B and Nie D: Cancer stem cells and resistance to chemo and radio therapy. Front Biosci 4: 2142-2149, 2012.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
11. Collins LG, Haines C, Perkel R and Enck RE: Lung cancer: diagnosis and management. Am Fam Physician 75: 56-63, 2007.
12. Li JY, Wang H, May S, et al: Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol 88: 11-17, 2008.
13. Antonyak MA, Kenyon LC, Godwin AK, et al: Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21: 5038-5046, 2002.
14. Tsuiki H, Tnani M, Okamoto I, et al: Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res 63: 250-255, 2003.
15. Cui J, Han SY, Wang C, et al: c-Jun NH2-terminal kinase 2α2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res 66: 10024-10031, 2006.
16. Khatlani TS, Wislez M, Sun M, et al: c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26: 2658-2666, 2007.
17. Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK and Wong AJ: The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene 30: 234-244, 2011.
18. Lee JJ, Lee JH, Ko YG, Hong SI and Lee JS: Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species. Oncogene 29: 561-575, 2010.
19. Perez EA, Hack FM, Fletcher TS and Chou TC: Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line. Oncol Res 6: 151-156, 1994.
20. Eramo A, Ricci-Vitiani L, Zeuner A, et al: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13: 1238-1241, 2006.
21. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008.
22. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon cancer-initiating cells. Nature 445: 111-115, 2007.
23. Sato A, Sunayama J, Okada M, et al: Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med 1: 811-824, 2012.
24. Bennett BL, Sasaki DT, Murray BW, et al: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98: 13681-13686, 2001.
25. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
26. Dhanasekaran DN and Reddy EP: JNK signaling in apoptosis. Oncogene 27: 6245-6251, 2008.
27. Verheij M, Ruiter GA, Zerp SF, et al: The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis. Radiother Oncol 47: 225-232, 1998.
28. Fan M and Chambers TC: Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 4: 253-267, 2001.
29. Cellurale C, Sabio G, Kennedy NJ, et al: Requirement of c-Jun NH2-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol 31: 1565-1576, 2011.
30. Jackson EL, Willis N, Mercer K, et al: Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248, 2001.
31. Vachtenheim J: Occurrence of ras mutations in human lung cancer. Minireview. Neoplasma 44: 145-149, 1997.
32. Kadara H, Kabbout M and Wistuba II: Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17: 50-65, 2012.
33. Kurtze I, Sonnemann J and Beck JF: KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. Oncol Rep 25: 1021-1029, 2011.
34. Okudela K, Hayashi H, Ito T, et al: K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Pathol 164: 91-100, 2004.